U.S., July 26 -- ClinicalTrials.gov registry received information related to the study (NCT07085559) titled 'Safety and Efficacy of Metabolically Armed BCMA CAR-T Cells (Meta10-BCMA) in the Treatment of r/r Plasma Cell Neoplasms Clinical Research' on July 14.

Brief Summary: A Study of Metabolically Armed BCMA CAR-T Cells Therapy for Patients With Relapsed and/or Refractory Plasma Cell Neoplasms.

Study Start Date: June 23

Study Type: INTERVENTIONAL

Condition: Multiple Myeloma (MM) Plasma Cell Leukemia (PCL) AL Amyloidosis (AL)

Intervention: DRUG: Metabolically Armed BCMA CAR-T cells.

Each subject receive metabolically armed BCMA CAR- T cells by intravenous infusion.

Recruitment Status: RECRUITING

Sponsor: Anhui Provincial Hospital...